Xilio reports $137.5M cash, appoints chair, gets $35.8M from warrants

Xilio Therapeutics, Inc.

Cash $137.5M at Dec 31, 2025, including $35.8M from Series B warrants; runway into Q2 2027.
Full exercise of Series B warrants by Coastlands Capital, Frazier Life Sciences, and Gilead.
Achieved milestone for masked antibody program under AbbVie; nominated CLDN18.2 T cell engager candidate.
Appointed Sara Bonstein as board chair, succeeding Paul Clancy who retired Jan 6, 2026.
Pipeline milestones: IND for XTX501 mid-2026, initial Phase 1 data H2 2027, STEAP1 candidate H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.